![Dennis Henner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dennis Henner
Direktor/Vorstandsmitglied bei
The Reed Institute
Profil
Dennis Henner, PhD, has been Managing Director of Clarus since the firm’s inception in 2005.
Prior to Clarus, Dr. Henner was a General Partner at MPM Capital, a healthcare venture capital firm.
He has over 30 years of direct industry and investment experience within the healthcare sector.
From 1981 to 2001, Dr. Henner was an executive at Genentech where he held various positions including Senior Vice President of Research, and was a member of Genentech's executive committee.
Dr. Henner received his PhD from the Department of Microbiology at the University of Virginia and did postgraduate training at the Scripps Clinic and Research Foundation.
Dr. Henner is a member of the Board of Trustees of Reed College.
Aktive Positionen von Dennis Henner
| Unternehmen | Position | Beginn |
|---|---|---|
The Reed Institute
 The Reed Institute Other Consumer ServicesConsumer Services Functions as a College/University | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Dennis Henner
| Unternehmen | Position | Ende |
|---|---|---|
| IMAGO BIOSCIENCES, INC. | Vorsitzender | 11.01.2023 |
| FORTY SEVEN, INC. | Direktor/Vorstandsmitglied | 07.04.2020 |
Clarus Ventures LLC
 Clarus Ventures LLC Investment ManagersFinance Clarus Ventures invests in companies located in the United States. The firm focuses on companies operating in the fields of biopharmaceutical and medical technology. It participates in early stage capital transactions. Clarus Ventures acquired by Blackstone Inc on November 30, 2018. Clarus ventures will become Blackstone Life Sciences. | Private Equity Investor | 30.11.2018 |
| AERIE PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 05.02.2015 |
| HUMANIGEN, INC. | Direktor/Vorstandsmitglied | 23.10.2013 |
Ausbildung von Dennis Henner
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
90
Beziehungen ersten Grades
26
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 26 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Rigel Pharmaceuticals, Inc.
 Rigel Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which discovers, develops and provides novel small-molecule drugs | Health Technology |
Xcyte Therapies, Inc.
 Xcyte Therapies, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic products | Health Technology |
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology Develops new therapeutics for endocrine system disorders | Health Technology |
Barrier Therapeutics, Inc.
 Barrier Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products in the field of dermatology | Health Technology |
Humanigen, Inc.
 Humanigen, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that engages in development of cell and gene therapies for treatment of cancers and infectious diseases | Health Technology |
Cellerant Therapeutics, Inc.
 Cellerant Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops stem cell-based cellular and antibody therapeutics for blood disorders and cancer | Health Technology |
Pelikan Technologies, Inc.
 Pelikan Technologies, Inc. Medical SpecialtiesHealth Technology Develops hand held diagnostic and monitoring devices | Health Technology |
Proacta, Inc.
 Proacta, Inc. BiotechnologyHealth Technology Develops drugs to treat cancer | Health Technology |
Ceregene, Inc.
 Ceregene, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for neurodegenerative disorders | Health Technology |
Aerie Pharmaceuticals, Inc.
 Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that discovers, develops and commercializes ophthalmic therapies for the treatment of patients with eye diseases | Health Technology |
SARcode Bioscience, Inc.
 SARcode Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
University of Virginia
 University of Virginia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MPM BioImpact LLC
 MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Finance |
The Scripps Research Institute
 The Scripps Research Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Reed Institute
The Reed Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rinat Neuroscience Corp.
 Rinat Neuroscience Corp. BiotechnologyHealth Technology Manufactures & markets drugs for treating neurological diseases | Health Technology |
Synergia Pharma, Inc.
 Synergia Pharma, Inc. Pharmaceuticals: OtherHealth Technology Develops clinical therapeutics | Health Technology |
CoMentis, Inc.
 CoMentis, Inc. Pharmaceuticals: MajorHealth Technology Focuses on developing drugs to treat various central nervous system disorders | Health Technology |
Clarus Ventures LLC
Clarus Ventures LLC Investment ManagersFinance Clarus Ventures invests in companies located in the United States. The firm focuses on companies operating in the fields of biopharmaceutical and medical technology. It participates in early stage capital transactions. Clarus Ventures acquired by Blackstone Inc on November 30, 2018. Clarus ventures will become Blackstone Life Sciences. | Finance |
FerroKin BioSciences, Inc.
 FerroKin BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Offers iron chelator for the treatment of iron-overload in patients | Health Technology |
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for cancer treatment | Health Technology |
Renato Corp.
 Renato Corp. Medical SpecialtiesHealth Technology Provides health diagnostic services | Health Technology |
SFJ Pharmaceuticals, Inc.
 SFJ Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops pharmaceuticals drugs | Health Technology |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company that develops medicine for oncology and neurodegeneration treatment | Health Technology |
Imago BioSciences, Inc.
 Imago BioSciences, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company that develops medicines for the treatment of myeloproliferative neoplasms and bone marrow diseases | Health Technology |
